Key result
New thrombosis in lupus anticoagulant-positive patients linked to ~495% higher mortality.
Why the study?
Data on the clinical course and mortality rates of lupus anticoagulant-positive individuals with or without thrombotic or pregnancy complications are limited.
Does the occurrence of a thrombotic event increase mortality in lupus anticoagulant-positive individuals?
Observational (n=151)
Does the occurrence of a thrombotic event increase mortality in lupus anticoagulant-positive individuals?
In patients with lupus anticoagulant, the occurrence of a new thrombotic event is a strong predictor of increased mortality, suggesting that preventing thromboembolism may improve survival.
Answers are grounded in this paper and cite their sources.
May support closer monitoring after thrombosis in lupus anticoagulant-positive patients; hypothesis-generating for prevention trials.
Data on the clinical course of lupus anticoagulant (LA)-positive individuals with or without thrombotic manifestations or pregnancy complications are limited. To investigate mortality rates and factors that might influence mortality, we conducted a prospective observational study of LA-positive individuals. In total, 151 patients (82% female) were followed for a median of 8.2 years; 30 of the patients (20%) developed 32 thromboembolic events (15 arterial and 17 venous events) and 20 patients (13%) died. In univariable analysis, new onset of thrombosis (hazard ratio [HR] = 8.76; 95% confidence interval [CI], 3.46-22.16) was associated with adverse survival. Thrombosis remained a strong adverse prognostic factor after multivariable adjustment for age and hypertension (HR = 5.95; 95% CI, 2.43-14.95). Concomitant autoimmune diseases, anticoagulant treatment at baseline, or positivity for anticardiolipin- or anti-β2-glycoprotein I antibodies were not associated with mortality. In a relative survival analysis, our cohort of LA positives showed a persistently worse survival in comparison with an age-, sex-, and study-inclusion-year-matched Austrian reference population. The cumulative relative survival was 95.0% (95% CI, 88.5-98.8) after 5 years and 87.7% (95% CI, 76.3-95.6) after 10 years. We conclude that occurrence of a thrombotic event is associated with higher mortality in patients with LA. Consequently, the prevention of thromboembolic events in LA positives might improve survival.
No takes yet. Share an insight, caveat, or question.
Gebhart et al. (2015) conducted an observational in Lupus anticoagulant (LA)-positive (n=151). New onset of thrombosis vs. No new onset of thrombosis was evaluated on Mortality (HR 5.95, 95% CI 2.43-14.95). New onset of thrombosis in lupus anticoagulant-positive patients was strongly associated with increased mortality after multivariable adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: